Journal of Clinical Trials
Open Access
ISSN: 2167-0870
ISSN: 2167-0870
Saud Mohamed Elsaughier*, Mohamed Kamal Salama, Amr Hanafy, Mahmoud M Ahmed and Ayman M Ibrahim
Background: HF biomarkers have growing importance in daily clinical practice as well as in clinical trials. Several biomarkers are used for diagnosis and prognosis of HF patients. Recently, Galectine-3 has been proposed for diagnosis and prognosis of HF. In this study we aimed to determine the relationship between galectine-3 level and cardiac functions in patients with chronic heart failure and its correlation with clinical manifestations. Methods: The current study enrolled 90 patients with chronic heart failure and then divided according to ejection fraction (EF) into two groups , group I included 60 patients with clinical manifestation of HF and EF <50%, group II included patients with clinical manifestation of HF and EF >50%.serum levels of Galectine-3 were measured in all patients with heart failure. Results: Level of galectine-3 was significantly increasing with advancing in NYHA classes [p value <0.001), while it had insignificant negative correlation with ejection fraction (r=0.06; P=0.51) and the Level of galactin-3 was significantly increasing with advancing in diastolic dysfunction grade (P= <0.001) Conclusion: Plasma galectine-3 concentration can be used as a biomarker to aid in clinical staging and severity of heart failure.
Published Date: 2020-04-10; Received Date: 2020-03-20